… cases with COVID-19 infection. Another neurological symptom of COVID-19 is impairment of
… being written, the use of rilonacept for severe COVID-19 infection has not been reported yet. …

… from RNA viruses—is a causative agent of a crucial respiratory infection known as COVID-19
in patients [1]. The genetic material of SARS-CoV-2, which is attached to the virus's …

… immunomodulating agents, including neutralizing monoclonal antibodies, corticosteroids,
and other molecules in the management of severe COVID-19, … confirmed COVID-19 infection …

… coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome
corona virus 2 … More than 3· 2 million people have been infected and more than 230 000 …

… based on immunomodulatory approach … COVID-19 patients. This could be very helpful in
offering novel insights and potential therapeutic agents for combating the COVID-19 infection. …

… immunomodulating drugs are scarce. Herein, we discuss the pathogenesis and the possible
role played by drugs … Patients with severe COVID-19 infection are at risk of acute respiratory …

… The pattern of MS1 cell expansion during COVID-19 infection was studied in four COVID-19 …
and viral infections, indicating the prognostic value of MS1 cells during secondary infections […

… Not yet recruiting Study of the safety of therapeutic Tx with Immunomodulatory MSC in
adults with COVID-19 infection requiring mechanical ventilation BM-Allo.MSC United States …

… The COVID-19 can be divided into 3 stadiums: the early infection, the … with COVID-19
showed that TNF-α inhibitor, either alone or in combination with other immunomodulatory drugs, …

… coronavirus 2 (SARS coronavirus 2, or SARS-CoV-2) is the cause of the respiratory infection
known as COVID-19. From … In the absence of proven antiviral agents or an effective vaccine, …